Checkpoint inhibitors are part of the family of immunotherapies and are increasingly being used in a wide variety of cancers. Immune-related adverse events pose a major challenge in the treatment of cancer patients. Pneumonitis is a rare immune-related adverse event that presents in distinct patterns. The goal of this chapter is to instruct readers on the incidence and clinical manifestations of pneumonitis and to offer guidance in the evaluation and treatment of patients with pneumonitis.
Keywords: Checkpoint inhibitors; Diffuse alveolar damage; Hypersensitivity pneumonitis; Immune-related adverse event; Nonspecific interstitial pneumonia; Organizing pneumonia; Pneumonitis; Thoracic imaging.